Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market 2034: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight

Chemotherapy Induced Peripheral Neuropathy companies working in the market are Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology as well as the Chemotherapy Induced Peripheral Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chemotherapy Induced Peripheral Neuropathy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chemotherapy Induced Peripheral Neuropathy market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Chemotherapy Induced Peripheral Neuropathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chemotherapy Induced Peripheral Neuropathy market.

Request for a Free Sample Report @ [https://www.delveinsight.com/report-store/cipn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Chemotherapy Induced Peripheral Neuropathy Market Report are:

* According to DelveInsight, Chemotherapy Induced Peripheral Neuropathy market size is expected to GROW by 2034.
* Leading Chemotherapy Induced Peripheral Neuropathy companies working in the market are Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.
* Key Chemotherapy Induced Peripheral Neuropathy Therapies expected to launch in the market are PledOx, Ibudilast, SON 080, AM 1710 and others.
* As per DelveInsight's estimate, the total incident population of chemotherapy induced peripheral neuropathy (CIPN) in the 7MM was ~1,618,000 in 2023.
* In the US, ~93,000 breast cancer patients developed CIPN, whereas other types of cancer (excluding lung, colorectal, pancreatic, and multiple myeloma cancer) patients represented more than 450,000 cases of CIPN.
* In 2023, the market size for CIPN in the US was approximately USD 910 million, and it is anticipated to grow positively, driven primarily by the rising incidence of cancer and the introduction of new therapies during the forecast period.
* In December 2020, for the development of ricolinostat, Regenacy announced a joint venture with 3E Bioventures in China, which will be further followed by a U.S.-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. This collaboration will evaluate the efficacy and safety of ricolinostat in patients having chemotherapy-induced peripheral neuropathy in China.

Chemotherapy Induced Peripheral Neuropathy Overview

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common and potentially debilitating side effect of certain chemotherapeutic agents. It results from damage to the peripheral nerves, which transmit signals between the brain, spinal cord, and the rest of the body. Common symptoms of CIPN include numbness, tingling, pain, and weakness, primarily in the hands and feet. These symptoms can significantly impair quality of life and, in severe cases, necessitate dose reduction or discontinuation of chemotherapy.

Agents frequently associated with CIPN include platinum-based drugs (e.g., cisplatin, oxaliplatin), taxanes (e.g., paclitaxel), and vinca alkaloids. The severity and progression of CIPN vary among individuals, influenced by factors such as the type of drug, dosage, and pre-existing conditions.

Management focuses on symptom relief and functional improvement, as no definitive cure exists. Strategies include dose adjustments, pharmacological interventions (e.g., antidepressants, anticonvulsants), and non-pharmacological therapies like physical therapy or acupuncture. Preventive measures and ongoing research into neuroprotective agents aim to mitigate CIPN's impact.

Understanding and addressing CIPN is crucial to improving treatment adherence and the overall well-being of cancer patients, making it an important consideration in oncology care.

Learn more about Chemotherapy Induced Peripheral Neuropathy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/sample-request/cipn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chemotherapy Induced Peripheral Neuropathy Market

The Chemotherapy Induced Peripheral Neuropathy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Chemotherapy Induced Peripheral Neuropathy market trends by analyzing the impact of current Chemotherapy Induced Peripheral Neuropathy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Chemotherapy Induced Peripheral Neuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chemotherapy Induced Peripheral Neuropathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chemotherapy Induced Peripheral Neuropathy market in 7MM is expected to witness a major change in the study period 2020-2034.

Chemotherapy Induced Peripheral Neuropathy Epidemiology

The Chemotherapy Induced Peripheral Neuropathy epidemiology section provides insights into the historical and current Chemotherapy Induced Peripheral Neuropathy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chemotherapy Induced Peripheral Neuropathy market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Chemotherapy Induced Peripheral Neuropathy Epidemiology @ [https://www.delveinsight.com/sample-request/cipn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chemotherapy Induced Peripheral Neuropathy Drugs Uptake

This section focuses on the uptake rate of the potential Chemotherapy Induced Peripheral Neuropathy drugs recently launched in the Chemotherapy Induced Peripheral Neuropathy market or expected to be launched in 2020-2034. The analysis covers the Chemotherapy Induced Peripheral Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Chemotherapy Induced Peripheral Neuropathy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Chemotherapy Induced Peripheral Neuropathy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chemotherapy Induced Peripheral Neuropathy Pipeline Development Activities

The Chemotherapy Induced Peripheral Neuropathy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chemotherapy Induced Peripheral Neuropathy key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Chemotherapy Induced Peripheral Neuropathy pipeline development activities @ [https://www.delveinsight.com/sample-request/cipn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chemotherapy Induced Peripheral Neuropathy Therapeutics Assessment

Major key companies are working proactively in the Chemotherapy Induced Peripheral Neuropathy Therapeutics market to develop novel therapies which will drive the Chemotherapy Induced Peripheral Neuropathy treatment markets in the upcoming years are Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.

Learn more about the emerging Chemotherapy Induced Peripheral Neuropathy therapies & key companies @ [https://www.delveinsight.com/sample-request/cipn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chemotherapy Induced Peripheral Neuropathy Report Key Insights

1. Chemotherapy Induced Peripheral Neuropathy Patient Population

2. Chemotherapy Induced Peripheral Neuropathy Market Size and Trends

3. Key Cross Competition in the Chemotherapy Induced Peripheral Neuropathy Market

4. Chemotherapy Induced Peripheral Neuropathy Market Dynamics (Key Drivers and Barriers)

5. Chemotherapy Induced Peripheral Neuropathy Market Opportunities

6. Chemotherapy Induced Peripheral Neuropathy Therapeutic Approaches

7. Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis

8. Chemotherapy Induced Peripheral Neuropathy Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Chemotherapy Induced Peripheral Neuropathy Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Chemotherapy Induced Peripheral Neuropathy Competitive Intelligence Analysis

4. Chemotherapy Induced Peripheral Neuropathy Market Overview at a Glance

5. Chemotherapy Induced Peripheral Neuropathy Disease Background and Overview

6. Chemotherapy Induced Peripheral Neuropathy Patient Journey

7. Chemotherapy Induced Peripheral Neuropathy Epidemiology and Patient Population

8. Chemotherapy Induced Peripheral Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Chemotherapy Induced Peripheral Neuropathy Unmet Needs

10. Key Endpoints of Chemotherapy Induced Peripheral Neuropathy Treatment

11. Chemotherapy Induced Peripheral Neuropathy Marketed Products

12. Chemotherapy Induced Peripheral Neuropathy Emerging Therapies

13. Chemotherapy Induced Peripheral Neuropathy Seven Major Market Analysis

14. Attribute Analysis

15. Chemotherapy Induced Peripheral Neuropathy Market Outlook (7 major markets)

16. Chemotherapy Induced Peripheral Neuropathy Access and Reimbursement Overview

17. KOL Views on the Chemotherapy Induced Peripheral Neuropathy Market

18. Chemotherapy Induced Peripheral Neuropathy Market Drivers

19. Chemotherapy Induced Peripheral Neuropathy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chemotherapy-induced-peripheral-neuropathy-cipn-treatment-market-2034-clinical-trials-medication-ema-pdma-fda-approvals-epidemiology-therapies-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit



This release was published on openPR.